SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Integrated BioPharma, Inc. (INBP) trades at a trailing P/E of 10.8. Trailing earnings yield is 9.25%. PEG 0.02 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (10.8); PEG ≤ 1.0 — Peter Lynch undervalued (0.02); earnings yield beats bond yields (9.25%).
- PEG Ratio 0.02 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 9.25% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Overall SharesGrow Score: 62/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — INBP
Valuation Multiples
P/E (TTM)10.8
Forward P/EN/A
PEG Ratio0.02
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.16
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.03
Book Value / Share$0.00
Revenue / Share$1.74
FCF / Share$0.00
Yields & Fair Value
Earnings Yield9.25%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.05 |
$42.21M |
$958K |
2.3% |
| 2017 |
$0.10 |
$46.95M |
$2.35M |
5% |
| 2018 |
$0.02 |
$43.71M |
$679K |
1.6% |
| 2019 |
$0.06 |
$49.98M |
$1.69M |
3.4% |
| 2020 |
$0.13 |
$52.77M |
$4.11M |
7.8% |
| 2021 |
$0.25 |
$63.56M |
$8.01M |
12.6% |
| 2022 |
$0.12 |
$56.25M |
$3.84M |
6.8% |
| 2023 |
$0.00 |
$50.67M |
$-34K |
-0.1% |
| 2024 |
$0.00 |
$50.32M |
$112K |
0.2% |
| 2025 |
$0.03 |
$54.35M |
$808K |
1.5% |
